IMM 6.33% 42.0¢ immutep limited

BrainyBoiler makes a good point but IMO just as probable that a...

  1. 384 Posts.
    lightbulb Created with Sketch. 5
    Brainy

    Boiler makes a good point but IMO just as probable that a Pharma comes in and funds the completion of Phase III. We will just have to wait and see.
    Personally, regarding current trends , I think it’s the smart money that’s buying in.

    Why ?
    Simply in regards to the science..there has NOT BEEN one piece of bad news to date( forget the shenanigans with Springtree and NASDAQ). Biotech’s are ALL about the science and to date the clinical trials have been positive.

    IMO, PRR ticks some key fudementals , including the following:
    (a) No bad news to date(since 2001). The company has a History of reporting good clinical results. Take this statement as you wish.
    (b) FDA Orphan drug designation - huge positive for companies entering last stage clinical development (Phase III).
    (c) Potency Assay for CVac being successfully developed ( ASX 14/6/2011) - critical !
    (d) Dr Neil Frazer credibility - say no more
    (e) Cvac - potentially a platform technology (mucin-1).
    Will only add to Pharma interest (on the back of positive Phase II results)

    (f) Matt Lehman taking over the CEO role:
    AS per Feb 12 update ..."Matt has extensive experience in the areas of clinical research, development programs and obtaining drug approval, and has specific expertise in clinical development strategies, operations and in-outsourcing. Prior to joining Prima he was chief operating officer for SPRI Clinical Trials in Europe.... Over the past decade Matt has been involved in approximately 150 clinical programs in a variety of roles "..
    ..well done Marty(champion) and the Board !

    BRR - what do take from Lehman accepting the appointment? In an industry (clinical trials and commercialisation ) where reputation for an aspiring COO can be shot overnight, I can only assume that he is across the current trials and I take his acceptance to be CEO as a vote of confidence for the future direction of the company.

    Prima BioMed will again presenting at the American Society of Clinical Oncology conference. Another opportunity to show case the technology to their colleagues and the world.

    PRR History..it will play a part.
    The above is my opinion only so please DYOR.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
42.0¢
Change
0.025(6.33%)
Mkt cap ! $598.3M
Open High Low Value Volume
39.5¢ 42.0¢ 39.5¢ $890.1K 2.163M

Buyers (Bids)

No. Vol. Price($)
3 127863 41.5¢
 

Sellers (Offers)

Price($) Vol. No.
42.5¢ 30850 2
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.